Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats. Nitric oxide (NO) synthesized from L-arginine is an endogenous vasodilator and inhibitor of platelet adhesion and aggregation. Gram-negative lipopolysaccharide (LPS) can induce NO synthesis, which may mediate the pathophysiologic effects of endotoxemia. In addition, our previous studies suggested that LPS-induced NO may protect against thrombosis in rats. In the present study, male SpragueDawley rats given LPS (0.1 mg/kg) i.p. increased their urinary excretion of NO2 + NO3 (stable end-products of NO) by 4.3-fold. Rats given 10 rg/kg/hr i.v. of nitroglycerin (GTN), an exogenous NO donor, showed a similar increase. L-NAME, an inhibitor of NO synthesis, abrogated the increase in urinary NO2 + NO3 in LPS-treated rats but not in rats given GTN. Glomerular thrombosis developed in rats given LPS + L-NAME (thrombosis score = 3.02 0.4), while those given LPS + L-NAME + GTN were largely protected (thrombosis score = 1.37 0.5, P < 0.05).
thrombosis in rats given LPS + L-NAME. We conclude that in endotoxemia, the antithrombogenic properties of endogenously synthesized NO are important in preventing alomerular thrombosis. The exogenously NO donor, GTN, can substitute for the antithrombogenic effect of endogenous NO. Clinically, administration of NO synthesis inhibitors to treat endotoxic shock may need to be combined with concomitant administration of exogenous NO donors to prevent microvascular thrombosis.
Endotoxin, a lipopolysacharide (LPS) from gram negative bacteria (LPS), and certain cytokines, have been demonstrated to induce endothelial injuly and intravascular coagulation, often leading to glomerular thrombosis [1] [2] [3] . LPS and/or cytokines, released during endotoxemia, increase expression of the inducible nitric oxide synthase (NOS) [4, 5] , leading to synthesis of large amounts of nitric oxide (NO) from its precursor L-arginine. NO induces vascular relaxation and inhibits platelet aggregation via increased synthesis of cGMP due to activation of soluble guanylate cyclase [6] . Thus, NO may play an important role in the hypotension observed during endotoxemia or sepsis [3] . On the other hand, in the kidney increased NO formation may be important in maintaining renal perfusion during shock and preventing platelet aggregation and thrombosis in glomeruli [7] . We have previously shown that rats given LPS have a marked increase in the urinary excretion rate of NO2 + NO3, the stable end products of NO, and do not develop glomerular thrombosis.
However, if LPS-induced synthesis of NO is prevented by prior or concomitant treatment with an L-arginine analog, such as NG nitro-L-arginine methyl ester ( L-NAME), generalized glomerular thrombosis occurs [7] .
In human septic shock, severe vasodilation, hypotension, vascular damage and disseminated intravascular coagulation can be observed. The persistent hypotension and low systemic vascular resistance are usually resistant to vasoconstrictors such as norepinephrine. Even in critical care units, the mortality rate of these patients remains high [8] . Recent reports have demonstrated that inhibition of NOS will quickly restore blood pressure to normal in both animals and humans with endotoxemia [9] [10] [11] . However, in rats and in dogs with endotoxemia the administration of an NOS inhibitor resulted in increased mortality [7, 12] . In a recent study, Wright, Rees and Moncada [13] reported that in rabbits that received LPS, blocking of NOS with an arginine analog, results in irreversible shock and increased mortality. The administration of an NO donor, S-nitroso-N-acetyl-penicillamine, improved perfusion, prevented shock and led to a decreased mortality. Unfortunately, intravascular coagulation or thrombosis was not investigated in that study.
If NOS inhibitors are to be useful in septic shock, adverse effects such as glomerular thrombosis will have to be prevented. We therefore undertook the present study to explore whether intravenous administration of an exogenous NO donor, nitroglycerin (glyceryl trinitrate, GTN), could substitute for endogenous NO and prevent glomerular thrombosis induced by LPS in L-NAME-treated rats, To evaluate whether the vasodilation induced by NO was important in the prevention of glomerular thrombosis, we compared the effect of GTN with that of two other vasodilators, atrial natriuretic peptide (ANP) and hydralazine. ANP has been shown to be effective in preventing acute renal failure after ischemia [14, 15] , and is known to increase cGMP via particulate guanylate cyclase. Hydralazine, on the other hand, causes direct vascular smooth muscle relaxation, probably via effects on calcium.
Methods

Experimental design
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The experimental design used in these studies is described in Figure 1 . Male Sprague-Dawley rats (275 to 350 g, Harlan Laboratories, Indianapolis, Illinois, USA) were used in all studies. Rats were fasted for six hours and then placed in metabolic cages from the femoral vein. Once awake, the rats were kept in individual metabolic cages for the seven hours of the experiment (Fig. 1) . The following five experimental groups were studied: Group 1. LPS + L-N4JvIE (N = 19). These rats were given LPS (0.1 mg/kg i.p.) at time 0 and L-NAME (75 mg/kg i.p.) at -30 minutes and 0, 2, 4 and 6 hours after the LPS injection. In five of these rats, a catheter was introduced in the femoral vein as described above. These rats received normal saline intravenously (1.2 ml/hr) beginning one hour before the LPS injection. These rats were used as controls to evaluate the effects of volume substitution and instrumentation as given in rats in the other groups.
Group 2. LPS + L-NAME + GTN (N = 15). L-NAME and LPS were given as in Group 1. In addition, GTN was dissolved in sterile saline in a glass vial, aspirated into a glass syringe and infused via the femoral vein catheter at a rate of 1.2 mI/hr. GTN infusion was started at -60 minutes, at 2 g/kg/min and increased stepwise to 10 jxg/kg/min over the next hour. This dose was continued for the rest of the experiment. Group 3, LPS + L-NAME + ANP (N = 12). LPS and L-NAME were given as in Group 1. In addition, ANP, dissolved in normal saline, was infused at a rate of 1.2 ml/hr, beginning at -60 minutes at 2 jxg/kg/hr with a stepwise increase to a maximum of 16 pg/kg/hr [14] , and kept at this rate for the duration of the experiment.
Group 4. GTN only (N 4). LPS and L-NAME were not given in this group. These rats were given only an infusion of GTN in normal saline in a concentration and at a rate identical to that given in Group 2.
Group 5. LPS only (N 15). These rats were injected i.p at time 0 with LPS (0.1 mg/kg). No other injections or infusions were
given.
An additional group of rats (N = 7) was given LPS + L-NAME and an intravenous infusion of a different vasodilator, hydralazine. The protocol for these experiments was exactly as for the groups given LPS + L-NAME + GTN or ANP. Based on previous studies [16] , we gave hydrazaline at a dose of 0.4 mg/kg/hr in a volume of 1.2 ml/hr, which resulted in blood pressures comparable to that in the LPS + L-NAME + GTN group.
To measure intrarterial blood pressure, subgroups of rats in each group (Group 1, 5 rats; Group 2, 4 rats; Group 3, 5 rats, Group 5, 3 rats), a PE-50 catheter was placed in the femoral artery for continuous blood pressure monitoring (TNF transducer, Gould, Oxnard, California, USA). As small doses of heparin were required to maintain line patency in these rats, kidney tissue from these rats was not used for the morphologic studies.
Seven hours (8 hr for group 5) after the injection of LPS, rats were anesthetized with mactin (5-butyl-5-ethyl-thiobarbituric acid, 100 mg/kg i.p.). The left kidney was removed through a midline incision and processed for morphologic analysis. A final blood sample was collected from the aorta and the animals killed by exsanguination.
Moi'phologic analysis Kidney tissue was fixed in buffered formalin and stained with the Periodic acid Schiff (PAS) technique. The stained sections were coded and read without knowledge of which group the tissue came from. The extent of the deposition of fibrin-like PAS positive material in the capillaries was evaluated. We have previously shown by immunofluorescence microscopy that these deposits do in fact contain fibrin [7] . The percentage of capillaries in each glomeruli which contained fibrin thrombosis was the basis for a semi-quantitative score: Score 0: No thrombosis seen; Score 1: some, but not more than 10%, of the glomerular capillaries showed thrombosis; Score 2: 10 to 25%; Score 3: 26 to 50%; Score 4: 51 to 100%. Fifty glomeruli were evaluated from each rat and the mean score for each group of rats was calculated.
Biochemical measurements
Urinary excretion rate of NO2 + NO3 was determined as previously described [7] . Urinary excretion of cyclic 3', 5'-guanosine monophosphate (cGMP) was determined by either enzyme-linked immunoassay or radioimmunoassay (Amersham, UK) [7, 14] . Both assays yielded similar results.
The following chemicals were used: N°-nitro-L-arginine methyl ester (L-NAME; Sigma Chemicals, St. Louis, Missouri, USA); lipopolysaccharide of E. col4 serotype 0127 (Difco, Detroit, 
Results
All rats that received LPS + L-NAME (Groups 1, 2 and 3) appeared lethargic and ill at the end of the experimental period. In Group 3 (LPS + L-NAME + ANP), all but 2 of the 12 rats became moribund and had to be killed early, between 3 and 6-1/2 hours after the injection of LPS.
Mean arterial blood pressures for rats in Groups 1, 2, 3 and 5 are shown in Figure 2 . Administration of LPS only was followed by a slight decrease in blood pressure from 137 5.6 before injection to 125 5.3 mm Hg at the end of the experiment. As expected, the blood pressure increased in all rats receiving L-NAME. The mean blood pressure values were not significantly different between all the groups that received L-NAME, but were significantly higher (P < 0.05) in these three groups compared to the "LPS only" Group at time 1, 3, 5 and 7 hours.
Urinary flow rate increased compared to baseline in all five experimental Groups 1,2, 3 and 5 ( Table 1 ). The increase was most marked for the LPS + L-NAME + GTN group, where it was more than four times the baseline level. No diuretic effect of ANP was noted in addition to that observed with LPS + L-NAME alone. Rats given GTN only (Group 4) did not show an increase in urinary flow rate. Urinary NO2 + NO3 excretion rates (UVNO2 + No3) are also shown in Table 1 . Injection of LPS resulted in a 4.3-fold increase in the urinary excretion rate of these endproducts of NO metabolism, compared to baseline. A similar increase in urinary excretion of NO2 + NO3 required a dose of GTN of 10 1.gJkg/min (Group 4, GTh only). L-NAME given with LPS (Group 1) completely inhibited the increase in the urinary NO2 + NO3 excretion. In fact there was a significant decrease in urinary excretion of the NO metabolites in both the LPS + L-NAME and the LPS + L-NAME + ANP groups, compared to baseline. GTN administration in LPS + L-NAME treated rats induced a significantly higher urinary excretion of NO2 + NO3 (P < 0.05 vs. LPS + L-NAME) which was similar to that obtained in rats given GTN alone. Thus L-NAME did not block the increase in NO2 + NO3 excretion resulting from GTN infusion. Urinary cGMP excretion rates for the experimental groups are shown in Table 2 . LPS caused an increase in the urinary excretion of cGMP (UVCGMP) of 1.7-fold compared to baseline. When L-NAME was given with LPS (Group 1) no increase occurred.
GTN alone (Group 4) caused no increase in urinary cGMP
excretion. The infusion of GTN in LPS + L-NAME treated rats also had no effect on cGMP excretion, while ANP infusion caused a substantial increase (P < 0.05 vs. Groups 1 and 2).
While rats injected with LPS only showed very little evidence of glomerular thrombosis, the animals that had been injected with LPS + L-NAME demonstrated extensive thrombosis, often involving the entire glomerular capillary bed (Fig. 3A) . The extent of thrombosis was similar in the subgroup of five rats who along with LPS and L-NAME also received an intravenous infusion of normal saline at a rate of 1.2 mi/hr (data not shown). For this reason these rats were included in the analysis of the LPS + L-NAME group. In the LPS + L-NAME + GTN group (Group 2), only scattered fibrin thrombin were seen in glomerular capillaries (Fig. 3B) . The thrombosis score was 1.37 0.5 in this group, compared to 3.02 0.4 (P < 0.025) for the LPS + L-NAME group, and not significantly different than in the LPS only group (0.59 0.4, P = 0.06). The administration of large doses of ANP did not protect the kidneys from thrombosis. The thrombosis score in rats treated with LPS + L-NAME + ANP was 2.68 0.5, not significantly different from that obtained in the LPS + L-NAME group (Fig. 4) .
In separate studies we also tested another NO-independent vasodilator, hydralazine. These rats developed glomerular thrombosis to a similar degree as rats treated with LPS + L-NAME or with LPS + L-NAME + ANP (data not shown). Like the LPS + Urine was collected for 7 hr, except in Group 3, where most of the rats died before the end of the experiment and the collection time was on the average 5 hr. a P < 0.05 vs. all others 
The experimental design is given in Figure 1 and in the Methods. The glomerular thrombosis score is based on the percentage of capillaries within a glomerulus which have thrombi. Data shown represent mean SEM from at least fifty glomeruli from each group. () denotes P < 0.05 versus both LPS + L-NAME and LPS + L-NAME + ANP groups.
L-NAME + ANP, rats receiving LPS + L-NAME + hydralazine also showed reduced survival time in this protocol. Discussion We have previously demonstrated that increased production of NO during endotoxemia was crucial in protecting against glomerular capillary thrombosis [7] . Rats given LPS increased their urinary excretion of NO2 + NO3 and did not show substantial fibrin deposition in the glomeruli. When the NO formation was inhibited with L-NAME, extensive glomerular thrombosis developed. L-NAME alone did not cause fibrin deposition [7] . In the current study, we have demonstrated that when endogenous NO synthesis is inhibited, exogenous nitric oxide can protect the glomeruli from endotoxin-induced thrombosis. As an exogenous NO donor we chose GTN [17, 18] , in a dose that gave a threefold increase in the urinary excretion of NO2 + NO3, to mimic the urinary excretion of NO metabolites seen in LPS-treated rats (Table 1) . In contrast ANP, a cGMP dependent but NO-independent vasodilator, caused no increase in the excretion of NO metabolites, and glomerular thrombosis was not prevented. Moreover, hydralazine, another powerful vasodilator with a different mechanism of action from either GTN or ANP, also failed to arrest glomerular thrombosis.
Since L-NAME in the dose used in this study acts as a vasoconstrictor [7, 19] , we thought it important to consider the possibility that L-NAME induced vasoconstriction and ischemia may contribute to the glomerular thrombosis seen in LPS-treated rats. Our findings argue against this contention for several reasons: (1) L-NAME alone does not cause glomerular thrombosis [7] ; (2) although organic nitrates are vasodilators, infusion of GTN in amounts similar to those used in the current study was found not to affect renal vascular resistance in rats [20] ; (3) ANP has been shown to ameliorate the development of acute renal failure caused by vasoconstriction and ischemia [14, 15] . However, we found that ANP administered in doses large enough to cause a substantial increase in urinary cGMP levels failed to prevent heavy fibrin deposition in the glomeruli; and (4) another unrelated vasodilator, hydralazine, also failed to prevent the glomerular thrombosis observed with LPS + L-NAME. Thus, we conclude that renal vasoconstriction, leading to a decrease in renal blood flow, does not account for the thrombosis observed in these rats.
Although there are many studies showing that GTN generates NO in vitro [21] [22] [23] , our study seems to be the first to show that the administration of an organic nitrate in vivo is followed by an increase in urinary excretion of NO metabolites. To our initial surprise, no increase in urinary cGMP occurred during GTN infusion, either when GTN was infused alone or together with LPS + L-NAME. Previous studies in our laboratory have shown an increase in urinary cGMP excretion in rats where NO synthesis was stimulated with acetylcholine [19] or LPS [7] . It is well established that organic nitrates, such as GTN, vasodilate through the activation of soluble guanylate cyclase resulting in an increase in intracellular cGMP [24, 25] . However, infusion of GTN was found not to increase the urinary excretion of cGMP in patients [26] . Furthermore, in patients with congestive heart failure, nitroglycerin ointment in doses sufficient to have a clear hemodynamic effect did not cause a measurable increase in plasma cGMP [27] . Thus, it appears that in vivo administration of organic nitrates does not result in increases in urinary cGMP, despite increases in NO metabolites in the urine. The reason for this disparity is not known.
This is the first study that shows that an organic nitrate can prevent the formation of glomerular thrombosis. However, an antithrombotic effect of nitrates has previously been suggested [28] . Platelet deposition on damaged endothelium in the carotid artery of pigs can be inhibited by organic nitrates [29] . Similarly, platelet aggregates in the retina of humans can be disaggregated using GTN [30] . Furthermore, patients treated with intravenous GTN have prolonged bleeding times and decreased platelet adhesion to endothelial cells [28, 31] . ANP, on the other hand, has not been found to affect platelets, presumably because ANP acts only on particulate guanylate cyclase, which is not present in platelets [32] . To further elucidate the action of GTN on platelets, we attempted to measure the cGMP content of platelets from the rats in our study [6, 33] . We found that in rats given LPS + L-NAME, the platelets had aggregated and could not be effectively separated from the erythrocytes. In rats given LPS + L-NAME + GTN, the platelets were not aggregated, but the lack of comparison groups made it impossible to assess the effect of GTN on platelet cGMP. However, the observation that platelets from LPS + L-NAME rats are highly aggregatory is consistent with the concept that platelet aggregation may contribute to the glomerular thrombosis we observe in these animals. Furthermore, the apparent correction of this enhanced aggregation in the LPS + L-NAME + GTN group, supports our hypothesis that exogenous NO protects against glomerular thrombosis by decreasing platelet aggregation. Based on our studies, we conclude that either nitric oxide, or a substance akin to it, is released from GTN in quantities sufficient to increase NO levels in vivo, as evidenced by the increased urinary NO2 + NO3 excretion. Furthermore, the NO produced from GTN prevents glomerular thrombosis in rats given LPS and inhibitors of endogenous NOS. We speculate that the prevention of glomerular capillary thrombosis by GTN is primarily due to the effect of NO on platelet function. If the use of inhibitors of NOS for the treatment of septic shock becomes clinically feasible, simultaneous treatment with nitroglycerin or similar exogenous NO donors may prevent intravascular coagulation and organ thrombosis.
